Coeptis Therapeutics Holdings, Inc. (COEPW) Stock Price, Financials & Summary

Price chart

Mar 25Mar 30Apr 2Apr 8Apr 13Apr 16Apr 21Apr 24

Key dataApr 24, 2026

Open$0.01

From 52W high−76.68%

Volume4.63M

Market cap$49348.93

P/E (TTM)—

P/S (TTM)0.0x

Div yield—

Key dataApr 24, 2026

Open

$0.01

From 52W high

−76.68%

Volume

4.63M

Market cap

$49348.93

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.4x

P/E (TTM)

—

RSI (14)

46.2

MomentumView details →

1D Return

+0.00%

YTD Return

−3.70%

SummaryUpdated Mar 1, 2026

Coeptis Therapeutics Holdings, Inc. (OTCMKTS:COEPW) is a biopharmaceutical company founded in 2017 and headquartered in Wexford, Pennsylvania. The company focuses on developing and commercializing both generic and branded pharmaceutical products, with a particular emphasis on innovative cell therapy platforms designed to treat various forms of cancer. Since its inception, Coeptis has evolved from a traditional pharmaceutical company into a biotechnology firm specializing in cutting-edge immunotherapy treatments, particularly those targeting specific cancer cell markers.

Ask drillr about Coeptis Therapeutics Holdings, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.4x

EV/Sales

−3.3x

P/S (TTM)

0.0x

P/B (TTM)

0.0x

ProfitabilityView details →

Gross Margin

87.23%

Net Margin

−839.69%

EBITDA Margin

−769.03%

ROE (TTM)

−69.12%

ROA (TTM)

−60.00%

Asset Turnover

0.07x

GrowthView details →

Revenue YoY

+2148.85%

EPS YoY

—

FCF YoY

−12.41%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+50.27%

EBITDA YoY

−9.44%

MomentumView details →

1D Return

+0.00%

YTD Return

−3.70%

1Y Return

−48.00%

RSI (14)

46.2

vs 50D SMA

−9.39%

vs 200D SMA

−44.98%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.25x

Quick Ratio

3.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.28

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.41M

Net Income (TTM)

−11.87M

Op. CF (TTM)

−8.00M

Latest newsMore news →

Z Squared Inc. acquired 100% of the membership interests of Paradox Data, LLC from Paradox Infrastructure LLC for up to $25 million in Series A Convertible Preferred Stock.6d ago

Similar companies

Celularity Inc.CELUW Revelation Biosciences, Inc.REVBW SeaStar Medical Holding CorporationICUCW Cingulate Inc.CINGW Vincerx Pharma, Inc.VINC Jasper Therapeutics, Inc.JSPRW Find similar companies →

Latest newsMore news →

Paradox Data LLC leased its building and approximately three-acre parcel in El Dorado, Arkansas to Paradox Infrastructure LLC for continued bitcoin mining operations at $1.00 per year base rent, with Z Squared Inc. liable for a one-time $500,000 relocation payment.6d ago Z Squared Inc. acquired 100% of the membership interests of Paradox Data, LLC from Paradox Infrastructure LLC for up to $25 million in Series A Convertible Preferred Stock.6d ago